Interest in, willingness-to-pay for and willingness-to-recommend genetic testing for prostate cancer among affected men after radical prostatectomy

This study aimed to gain insight into men ’s attitudes in genetic testing for PCa. 4699 men with PCa from the German multicenter prospective database “Familial Prostate Cancer” were included. Interest in, Willingness-to-pay for and Willingness-to-recommend a genetic test for PCa were quantified. Associations with several sociodemograp hic and psychosocial variables were evaluated by logistic regression. 76.8% of the affected men with a median follow-up of 12.9 years were interested in a genetic test for PCa. Newly identified variables significantly associated with interest were having sons (OR 1.66, p 
Source: Familial Cancer - Category: Cancer & Oncology Source Type: research

Related Links:

CONCLUSIONS Eriocalyxin B induces apoptosis and autophagy involving the Akt/mTOR pathway in prostate cancer cells in vitro. These findings provide evidence for Eriocalyxin B as a potent therapeutic for the treatment of prostate cancer. PMID: 31714902 [PubMed - in process]
Source: Medical Science Monitor - Category: Research Tags: Med Sci Monit Source Type: research
Publication date: Available online 12 November 2019Source: Progress in NeurobiologyAuthor(s): Joseph H. Neale, Tatsuo YamamotoAbstractN-Acetylaspartylglutamate (NAAG) is the third most prevalent neurotransmitter in the mammalian nervous system, yet its therapeutic potential is only now being fully recognized. Drugs that inhibit the inactivation of NAAG by glutamate carboxypeptidase II (GCPII) increase its extracellular concentration and its activation of its receptor, mGluR3. These drugs warrant attention, as they are effective in animal models of several clinical disorders including stroke, traumatic brain injury and schi...
Source: Progress in Neurobiology - Category: Neuroscience Source Type: research
Sepsis affects around 260,000 people a year in the UK and 1.7million in the US. It causes more avoidable deaths than breast, bowel and prostate cancer combined.
Source: the Mail online | Health - Category: Consumer Health News Source Type: news
Contrast developer Guerbet has signed a strategic partnership with healthcare...Read more on AuntMinnie.comRelated Reading: Guerbet, IBM partner on AI for prostate cancer Guerbet revenues slow in 2nd quarter Guerbet wins group purchasing agreement from Premier Guerbet opens manufacturing site for Lipiodol Guerbet releases new version of Contrast&Care
Source: Headlines - Category: Radiology Source Type: news
Authors: Ghashghaei M, Kucharczyk M, Elakshar S, Muanza T, Niazi T Abstract Background: Prostate cancer (pca) is the most common non-dermatologic cancer and the 3rd leading cause of male cancer mortality in Canada. In patients with high-risk localized or recurrent pca, management typically includes the combination of long-term androgen deprivation therapy (adt) and radiotherapy (rt). New androgen-receptor-axis targeted therapies (arats), which await validation, offer an option to intensify therapy. Methods: In this narrative review, we report the relevant history that has supported combining adt with rt. The li...
Source: Current Oncology - Category: Cancer & Oncology Tags: Curr Oncol Source Type: research
CONCLUSIONS: In France, end-of-life management of men with PCa, regardless of the cause of death, is centered on SSH and HPC, essentially at the time of death. Certain indicators of end-of-life management were particular high. LEVEL OF EVIDENCE: 4. PMID: 31708329 [PubMed - as supplied by publisher]
Source: Progres en Urologie - Category: Urology & Nephrology Tags: Prog Urol Source Type: research
Journal Name: Clinical Chemistry and Laboratory Medicine (CCLM) Issue: Ahead of print
Source: Clinical Chemistry and Laboratory Medicine - Category: Laboratory Medicine Source Type: research
ACS Applied Materials&InterfacesDOI: 10.1021/acsami.9b15195
Source: ACS Applied Materials and Interfaces - Category: Materials Science Authors: Source Type: research
(Medical College of Georgia at Augusta University) A transcription factor that aids neuron function also appears to enable a cell conversion in the prostate gland that can make an already recurrent cancer even more deadly, scientists say.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news
Publication date: Available online 12 November 2019Source: European UrologyAuthor(s): Guillaume Ploussard
Source: European Urology - Category: Urology & Nephrology Source Type: research
More News: Cancer | Cancer & Oncology | Databases & Libraries | Education | Genetics | Germany Health | Prostate Cancer | Study | Universities & Medical Training